Encouragingly, in a mouse model of KG-1 AML, NKG2D CAR/IL15-NK treatment significantly prolonged the survival of mice and even achieved complete tumor regression after multiple injections [146]. This evidence concerns the gene IL15 and acute myeloid leukemia.